Health improvement and viral suppression in persons receiving antiretroviral treatment in Cameroo
Not Applicable
- Conditions
- B20F32Human immunodeficiency virus [HIV] disease resulting in infectious and parasitic diseasesDepressive episode
- Registration Number
- DRKS00027440
- Lead Sponsor
- Research for Development international Foundation
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 370
Inclusion Criteria
Any person 13 years and above who is living with HIV who has been on treatment 6-9months prior start of the study. This person has to be aware of their serological status and implicated in their treatment.
Exclusion Criteria
Persons 10-12 years of age, prisoners, those who were unable to understand the study as well as those who were not aware of their serological status nor implicated in their treatment.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The antiretroviral treatment suppression levels of the participants will be measured at the endpoint of the study using viral load measurement system setup within the country (GeneXpert® HIV-1 Viral Load, Cepheid or Generic HIV-1 Charge Virale, Biocentric). Any participant will be considered suppressed if the viral load was less than 1000 copies per ml.
- Secondary Outcome Measures
Name Time Method The antiretroviral treatment adherence levels of participants will be measured at baseline, at month-6, and at month-12 of follow-up using the multi-method adherence measurement tool which is a questionnaire constituting of drug refill, pill identification test, self-reported adherence, visual analog scale, and pill count. This tool is overall graded from 5-10 where participants will be considered poorly, moderately, and highly adherent if they have scores between 5-9, 10-14, and 15 respectively.